KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified manufacturing sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Non-phthalate and formulated without animal- derived substances • Standard concentrates in a PE carrier and on request in PP • Pre-colored formulations can be supplied in specific resins selected for the application REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) • Food contact established with FDA/EU* APPLICATION BULLETIN DRUG TYPE COLOR DESCRIPTION PANTONE REFERENCE AVIENT PRODUCT CODE PE BASED Adrenergic agonist combinations Light Green 373 C PE6M176349 Adrenergic agonists Purple 2583 C PE4M176057 Anti-infectives Tan 467 C PE8M176130 Anti-inflammatory, nonsteroidal Grey Cool Grey 4 C PE7M176184 Anti-inflammatory, steroids Pink 197 C PE3M176237 Anti-inflammatory, immunomodulators Olive Green 5763 C On request Beta-blockers Yellow Yellow C PE1M176160 Beta-blocker combinations Dark Blue 281 C PE5M176272 Carbonic anhydrase inhibitors Orange 1585 C PE2M176089 Cytotoxic Black 6 C PL9M176008 Miotics Dark Green 348 C PE6M176267 Mydriatics and cycloplegics Red 1797 C PE3M176236 Prostaglandin analogues Turquoise 326 C PE5M176273 Healthcare use limitations apply—see below.

The list below provides links to pdf files for Avient's ISO Certifications (ISO Certificates).

http://www.art.canaco.org https://www.avient.com/sites/default/files/2020-11/gls-acqua-plose-case-study.pdf 1http://store.elsevier.com/Handbook-of-Polymer-Applications-in-Medicine- and-Medical-Devices/isbn-9780323221696/ Tear Resistance PERFORMANCE COMPARISON In Handbook of Polymer Applications in Medicine and Medical Devices,1 Laurence W. The results were impressive: • Better tension set, improved compression and enhanced permeability • Slashed $70,000 from production costs by reducing cycle times and eliminating assembly steps • Lower specific gravity of TPEs trimmed overall part weight, which cut $36,000 in annual freight costs • Reprocessability of TPEs shrank scrap rates, saving more than $70,000 in material waste SWITCH TO TPEs BOOSTS BOTTOM LINE CASE STUDY READ MORE ONLINE For a manufacturer seeking to redesign a liquid injection-molded silicone medical pump valve insert, Avient suggested custom-formulated grades of Dynalloy™ OBC and Versaflex™ TPEs that would deliver better multi-functional performance than the previous design, while also facilitating easier two-shot molding.

news library online, please visit www.avient.com/news. SEC Filings

news library online, please visit www.polyone.com/news. SEC Filings

news library online, please visit www.avient.com/news. SEC Filings

news library online, please visit www.avient.com/news. SEC Filings

news library online, please visit www.avient.com/news. SEC Filings

Mesa, Comptek, SilCoTec, Gordon Composites and Polystrand, including whether such businesses will be accretive, retain the management teams of acquired businesses, and retain relationships with customers of acquired businesses; disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the financial condition of our customers, including the ability of customers (especially those that may be highly leveraged and those with inadequate liquidity) to maintain their credit availability; the speed and extent of an economic recovery, including the recovery of the housing market; our ability to achieve new business gains; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; changes in polymer consumption growth rates and laws and regulations regarding the disposal of plastic in jurisdictions where we conduct business; changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; fluctuations in raw material prices, quality and supply and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to working capital reductions, cost reductions and employee productivity goals; an inability to raise or sustain prices for products or services; an inability to maintain appropriate relations with unions and employees; our ability to continue to pay cash dividends including at the increasing rate, which will be subject to, among other factors, market conditions, our cash flow and cash requirements and restrictions contained in any of our debt agreements; the amount and timing of repurchases of our common shares, if any; and other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation. SEC Filings

To access Avient's news library online, please visit www.avient.com/news SEC Filings